Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

Benzer Materyaller

• Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
  Yazar:: Kavanaugh, Arthur, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
  Yazar:: Kavanaugh, Arthur, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
  Yazar:: Kavanaugh, Arthur, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
  Yazar:: Kavanaugh, Arthur, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Secukinumab: A New Treatment Option for Psoriatic Arthritis
  Yazar:: Mease, Philip, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)